Exploration of a library of triazolothiadiazole and triazolothiadiazine compounds as a highly potent and selective family of cholinesterase and monoamine oxidase inhibitors: design, synthesis, X-ray diffraction analysis and molecular docking studies

• Published in: RSC advances 2015-01, Vol.5 (27), p.21249-21267
• Main Authors: Khan, Imtiaz, Bakht, Syeda Mahwish, Ibrar, Aliya, Abbas, Saba, Hameed, Shahid, White, Jonathan M., Rana, Usman Ali, Zaib, Sumera, Shahid, Mohammad, Iqbal, Jamshed
• Format: Article
• Language: English
• Subjects: Demand; Diffraction; Drugs; Inhibition; Inhibitors; Libraries; Oxidase
• ISSN: 2046-2069; 2046-2069
• DOI: 10.1039/C5RA00906E

There is a high demand for the collection of small organic molecules (especially N -heterocycles) with diversity and complexity in the process of drug discovery. This need for privileged scaffolds in medicinal research gives an impetus for the development of nitrogen-containing compounds which are widely encountered in natural products, drugs and pharmaceutically active compounds. In this context, a diverse library of new triazolothiadiazole ( 4a–l ) and triazolothiadiazine ( 5a–p ) compounds was designed, synthesized and evaluated as potent and selective inhibitors of electric eel acetylcholinesterase (EeAChE) and horse serum butyrylcholinesterase (hBChE) by Ellman's method using neostigmine and donepezil as standard inhibitors. Among the screened triazolothiadiazoles, 4j emerged as a lead candidate showing the highest inhibition with an outstanding IC 50 value of 0.117 ± 0.007 μM against AChE, which is ∼139-fold greater inhibitory efficacy as compared to neostigmine, whereas 4k displayed ∼506-fold strong inhibition with IC 50 of 0.056 ± 0.001 μM against BChE. In the triazolothiadiazine series, 5j and 5e depicted a clear selectivity towards EeAChE with IC 50 values of 0.065 ± 0.005 and 0.075 ± 0.001 μM, respectively, which are ∼250- and ∼218-fold stronger inhibition as compared to neostigmine (IC 50 = 16.3 ± 1.12 μM). In addition, the synthesized compounds were also tested for their monoamine oxidase (MAO-A and MAO-B) inhibition, where 4a from the triazolothiadiazole series delivered the highest potency against MAO-A with an IC 50 value of 0.11 ± 0.005 μM which is ∼33-fold higher inhibition as compared to the standard inhibitor, clorgyline (IC 50 = 3.64 ± 0.012 μM), whereas compound 5c from the triazolothiadiazine series turned out to be a lead inhibitor with an IC 50 value of 0.011 ± 0.001 μM which is ∼330-fold stronger inhibition. Moreover, compounds 4b (triazolothiadiazole series) and 5o (triazolothiadiazine series) were identified as lead inhibitors against MAO-B. Molecular modelling studies were performed against human AChE and BChE to observe the binding site interactions of these compounds.